Fevipiprant, a selective prostaglandin D-2 receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by group 2 innate lymphoid cells
Príomhchruthaitheoirí: | Xue, L, Hardman, C, Chen, W, Batty, P, Ogg, G, Erpenbeck, V, Sandham, D |
---|---|
Formáid: | Conference item |
Foilsithe / Cruthaithe: |
American Thoracic Society
2018
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
de réir: Chen, W, et al.
Foilsithe / Cruthaithe: (2018) -
Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
de réir: Sandham, D, et al.
Foilsithe / Cruthaithe: (2019) -
Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function
de réir: Hardman, C, et al.
Foilsithe / Cruthaithe: (2019) -
Fevipiprant, a selective prostaglandin D(2)receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by Tc2 cells (type-2 CD8(+)lymphocytes)
de réir: Xue, L, et al.
Foilsithe / Cruthaithe: (2019) -
Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma
de réir: Veit J. Erpenbeck, et al.
Foilsithe / Cruthaithe: (2016-12-01)